NasdaqGS - Nasdaq Real Time Price USD

10x Genomics, Inc. (TXG)

Compare
15.74 -0.17 (-1.07%)
At close: October 16 at 4:00 PM EDT
15.84 +0.10 (+0.64%)
Pre-Market: 9:14 AM EDT
Loading Chart for TXG
DELL
  • Previous Close 15.91
  • Open 16.00
  • Bid 15.56 x 600
  • Ask 15.71 x 100
  • Day's Range 15.46 - 16.36
  • 52 Week Range 14.02 - 57.90
  • Volume 2,105,139
  • Avg. Volume 1,851,893
  • Market Cap (intraday) 1.897B
  • Beta (5Y Monthly) 1.85
  • PE Ratio (TTM) --
  • EPS (TTM) -2.03
  • Earnings Date Oct 29, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 24.71

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

www.10xgenomics.com

1,259

Full Time Employees

December 31

Fiscal Year Ends

Recent News: TXG

View More

Performance Overview: TXG

Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TXG
71.87%
S&P 500
22.49%

1-Year Return

TXG
59.13%
S&P 500
35.00%

3-Year Return

TXG
89.66%
S&P 500
30.66%

5-Year Return

TXG
67.65%
S&P 500
95.03%

Compare To: TXG

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TXG

View More

Valuation Measures

Annual
As of 10/16/2024
  • Market Cap

    1.90B

  • Enterprise Value

    1.61B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.96

  • Price/Book (mrq)

    2.62

  • Enterprise Value/Revenue

    2.54

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -37.96%

  • Return on Assets (ttm)

    -11.95%

  • Return on Equity (ttm)

    -31.60%

  • Revenue (ttm)

    631.73M

  • Net Income Avi to Common (ttm)

    -239.78M

  • Diluted EPS (ttm)

    -2.03

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    380.09M

  • Total Debt/Equity (mrq)

    12.36%

  • Levered Free Cash Flow (ttm)

    62.79M

Research Analysis: TXG

View More

Company Insights: TXG

Research Reports: TXG

View More

People Also Watch